

EPIX Pharmaceuticals, Inc.  
Form 8-K  
October 27, 2004

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT PURSUANT**

**TO SECTION 13 OR 15(D) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **October 26, 2004**

**EPIX Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**000-21863**  
(Commission File Number)

**04-3030815**  
(IRS Employer Identification No.)

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form 8-K

**161 First Street, Cambridge, Massachusetts 02142**

(Address of Principal Executive Offices)

(Zip Code)

**(617) 250-6000**

(Registrant's Telephone Number, Including Area Code)

**EPIX Medical, Inc.**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---



**Item 2.02. Financial Information.**

On October 26, 2004, EPIX Pharmaceuticals, Inc. issued a press release that announced its financial results for the third quarter 2004 and provided an update on the regulatory status of the New Drug Application (NDA) for MS-325, the Company's lead imaging pharmaceutical designed for Magnetic Resonance Angiography (MRA). A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

(c) The following exhibits are furnished with this report:

<b>Exhibit Number</b>		<b>Description</b>
99.1		Press Release dated October 26, 2004.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**EPIX Pharmaceuticals, Inc.**  
(Registrant)

Date: October 26, 2004

/s/ Peyton J. Marshall  
Peyton J. Marshall  
*Senior Vice-President,  
Finance and Administration,  
Chief Financial Officer*